Should You Buy Illumina, Inc. (NASDAQ:ILMN) On Current Analyst Views?

Adjust Comment Print

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. (NASDAQ:ILMN). According to the most recently released broker notes, 4 analysts have a rating of "strong buy" on the stock, 5 analysts "buy", 7 analysts "neutral", 2 analysts "sell" and 1 analysts "strong sell". Analysts mean target price for The McClatchy Company (NYSE:MNI) is $37.00 while their mean recommendation is 2.00 (1=Buy, 5=sell).

Looking ahead, ILMN forecast Q2 EPS of $0.65 to $0.70, well below the $0.87 that analysts are looking for. Deutsche Bank AG restated a hold rating and set a $160.00 price target on shares of Illumina in a research report on Wednesday, January 18th. Piper Jaffray Companies reissued an overweight rating and set a $187.00 target price (up from $170.00) on shares of Illumina in a research note on Friday, April 14th. Bank of America Corp upgraded shares of Illumina from a neutral rating to a buy rating and increased their price target for the company from $145.00 to $175.00 in a research report on Tuesday, January 10th. Vetr raised Illumina from a "buy" rating to a "strong-buy" rating and set a $196.75 price target for the company in a report on Monday. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of "Hold" and an average price target of $161.27. A total of 2.75 million shares exchanged at hands and its average trading volume is standing at 0.93 million shares. Latest closing price was -8.73% below its 50-day moving average and 9.06% above its 200-day moving average. The firm has a market capitalization of $26.85 billion, a P/E ratio of 59.77 and a beta of 0.79. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $186.88.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, April 25th.

Return on Assets (ROA) for Illumina, Inc. The business earned $619 million during the quarter, compared to the consensus estimate of $612.50 million.

Trump Drops Opposition to Obamacare Payments to Avoid Government Shutdown
House Republicans have stated before that these are illegal payments because Congress never authorized the subsidy. West Virginia Senator Joe Manchin III and several Democrats request the extension of the miners' benefits.

They expect $0.64 EPS, down 10.94% or $0.07 from last year's $0.71 per share. Illumina's revenue for the quarter was up 4.5% on a year-over-year basis. If you are accessing this report on another website, it was stolen and republished in violation of United States & worldwide trademark and copyright legislation. "(ILMN) Updates Q2 Earnings Guidance" was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of worldwide trademark and copyright law. LLC now owns 600 shares of the life sciences company's stock valued at $109,000 after buying an additional 560 shares during the last quarter. The stock was sold at an average price of $172.72, for a total transaction of $518,160.00. Following the completion of the transaction, the director now owns 18,704 shares of the company's stock, valued at approximately $3,230,554.88. Also, SVP Charles Dadswell sold 572 shares of the business's stock in a transaction dated Monday, February 6th. Following the transaction, the executive vice president now owns 27,949 shares in the company, valued at $4,496,994.10. The disclosure for this sale can be found here. During the trading on 04/21/2017, Company's stock ranged from $32.55 to $31.65.

Hedge funds have recently bought and sold shares of the stock.

Pictet & Cie Europe Sa increased Illumina Inc (ILMN) stake by 23.18% reported in 2016Q4 SEC filing. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company's stock valued at $373,000 after buying an additional 35 shares during the last quarter. LLC boosted its position in Illumina by 1,400.0% in the third quarter. Tower Bridge Advisors acquired a new stake in shares of Illumina during the third quarter valued at $221,000. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.